Sodium acetate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for sodium acetate and what is the scope of patent protection?
Sodium acetate
is the generic ingredient in one branded drug marketed by Fresenius Kabi Usa, Hikma, Hospira, and Milla Pharms, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.There are nine drug master file entries for sodium acetate. Five suppliers are listed for this compound.
Summary for sodium acetate
US Patents: | 0 |
Tradenames: | 1 |
Applicants: | 4 |
NDAs: | 4 |
Drug Master File Entries: | 9 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 230 |
Patent Applications: | 3,898 |
Drug Prices: | Drug price trends for sodium acetate |
What excipients (inactive ingredients) are in sodium acetate? | sodium acetate excipients list |
DailyMed Link: | sodium acetate at DailyMed |
Pharmacology for sodium acetate
Drug Class | Osmotic Laxative |
Mechanism of Action | Osmotic Activity |
Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
Anatomical Therapeutic Chemical (ATC) Classes for sodium acetate
US Patents and Regulatory Information for sodium acetate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikma | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 216920-003 | Mar 15, 2024 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Hospira | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 018893-001 | May 4, 1983 | AP | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Fresenius Kabi Usa | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 206687-001 | Oct 30, 2017 | AP | RX | No | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Hospira | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 018893-003 | Sep 2, 2014 | AP | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Milla Pharms | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 214805-001 | May 4, 2021 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Hikma | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 216920-002 | Mar 15, 2024 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Hospira | SODIUM ACETATE | sodium acetate | SOLUTION;INTRAVENOUS | 018893-002 | Sep 2, 2014 | AP | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Sodium acetate Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.